Restless Legs Syndrome Clinical Trial
Official title:
d Immobilization Test (SIT) Test for Early Detection of Restless Legs Syndrome (RLS) Augmentation - Proof of Concept
Some medications used to treat the restless legs syndrome (RLS) when taken for some time make the condition worse. This study seeks to find a method for early detection of this problem so that it can either be prevented or corrected.
Long term dopaminergic treatment of RLS produces an exacerbation of RLS symptoms worse than
before treatment for a significant percentage (5 - 70%) of those treated. This appears to be
related to half-life, dose and duration of treatment. Shorter half-life medications appear
to produce more augmentation. Once started augmentation appears to be progressive in many of
the patients with the end result that the patient has much more severe RLS symptoms than
before treatment. These symptoms can still be temporarily reduced by adding more
dopaminergic treatment, but eventually this fails to suffice even with very high
dopaminergic doses. The problem is finding a way to detect augmentation early during
dopamine treatment both to determine the true rate of occurrence of this problem and to
change treatment strategies before the problem becomes severe.
The suggested immobilization test creates the stimulus situation of protracted rest while
lying down that provokes RLS symptoms. It provides a sensitive test for the severity of the
symptom.. It should therefore provide an early detection of any exacerbation of symptoms
such as that occurring with RLS augmentation.
In addition diphenhydramine also creates an exacerbation of RLS symptoms. This exacerbation
would amplify the current severity of the RLS and as such could provide a tool for enhancing
the degree of augmentation. Thus testing with a diphenhydramine challenge dose before the
SIT test could provide an even more sensitive measure of augmentation
The investigators specifically hypothesize:
1. The objective measures from the SIT test will reveal an increase in severity of RLS
that occurs with RLS augmentation at the same time or before the augmentation is
detected by the usual subjective clinical assessments.
2. An oral dose of 25 mg of diphenhydramine taken 45 minutes before a SIT test will
amplify the augmentation effects shown on the objective measures of the SIT. This will
provide an enhanced detection of augmentation before or at the same time as that
detected by either the SIT test alone or the clinical evaluation.
This study may for the first time provide a standard highly repeatable objective measure of
RLS augmentation that is as or more sensitive as a very careful clinical evaluation by
someone well trained in detecting RLS augmentation. As such it would prove clinically useful
to evaluate RLS treatment progress. It would also provide an efficient method for evaluating
the augmentation potential of new medications for RLS. .
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04786314 -
The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome
|
N/A | |
Completed |
NCT01455012 -
Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
|
Phase 4 | |
Terminated |
NCT01192503 -
Safety and Efficacy of Rasagiline in Restless Legs Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT00530530 -
ASP8825 - Study in Patients With Restless Legs Syndrome
|
Phase 2 | |
Completed |
NCT00721279 -
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
|
N/A | |
Completed |
NCT00375284 -
A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
|
Phase 4 | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00479531 -
Sequential Compression Devices for Treatment of Restless Legs Syndrome
|
Phase 3 | |
Recruiting |
NCT05581576 -
Pitolisant in Refractory Restless Legs Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03218969 -
Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
|
Phase 1/Phase 2 | |
Recruiting |
NCT04144790 -
Impact of Iron Supplementation Treatment on Brain Iron Concentrations
|
||
Completed |
NCT05787080 -
Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS)
|
N/A | |
Not yet recruiting |
NCT05529095 -
Sublingual Apomorphine in Refractory Restless Legs Syndrome
|
Phase 4 | |
Recruiting |
NCT05044520 -
Clinical Features Associated With Restless Legs Syndrome.
|
||
Withdrawn |
NCT03849001 -
Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS
|
N/A | |
Completed |
NCT03076541 -
Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.
|
N/A | |
Recruiting |
NCT04145674 -
A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo
|
Phase 2 | |
Completed |
NCT02532608 -
Infra-slow Oscillations During Sleep
|
N/A | |
Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|
||
Completed |
NCT00748098 -
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
|
Phase 3 |